最新医学別冊　診断と治療のABC138　高TG血症

出版社： 最新医学社
発行日： 2018-09-01
分野： 臨床医学：一般  >  雑誌
ISSN： 03708241
雑誌名：
特集： 高TG血症
電子書籍版： 2018-09-01
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

目次

  • 特集　高TG血症

    MAP　眼で見る高TG血症

    第１章　概念・定義と疫学
    　高TG血症の定義・分類・原因
    　高TG血症と心血管イベントの疫学

    第２章　病因・病態生理
    　高TG血症の遺伝子解析と遺伝的背景
    　食後レムナントリポタンパクと高TG血症
    　レムナントリポ蛋白と動脈硬化
    　高TG血症とインスリン抵抗性
    　高TG血症とHDL代謝
    　SREBPによる脂質代謝調節
    　多臓器連関による脂質代謝調節
    　脂肪組織線維化の制御メカニズム

    第３章　診断
    　TGの測定法と標準化
    　原発性高TG血症の鑑別診断の進め方

    第４章　管理・治療
    　高TG血症の管理と治療
    　　１．食事指導
    　　２．運動療法
    　　３．治療薬剤
    　　　１）フィブラート系
    　　　２）多価不飽和脂肪酸
    　　　３）スタチン
    　　　４）エゼチミブ
    　高TG血症に関連する疾患の管理と治療
    　　１．急性膵炎
    　　２．NASH/NAFLD
    　　３．慢性腎臓病（CKD）
    　各病態における高TG血症の管理
    　　１．原発性高TG血症治療の現状と新薬開発状況
    　　２．糖尿病・メタボリックシンドローム

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・定義と疫学

P.22 掲載の参考文献
1) 日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン p14. 2017.
 
2) Botham K M, et al : Lipid transport and Strorage. In : Harper's Illustrated Biochemistry 30th edition. The McGraw-Hill Education, 2015.
 
3) Pownall H J, et al : Human plasma lipoprotein metabolism. In : Clinical lipidology : acompanion to Braunwald's heart disease. 1st ed. (Ballantyne CM ed) Elsevier, Philadelphia, 2009.
 
4) Ramasamy I : Update on the molecular biology of dyslipidemias. Clin Chim Acta 454 : 143-185, 2016.
PubMed
5) Pownall H J, et al : Human plasma lipoprotein metabolism. In : Clinical lipidology : acompanion to Braunwald's heart disease. 2nd ed. (Ballantyne CM ed) Elsevier, Philadelphia, 2015.
 
6) Fisher E A : GPIHBP1 : lipoprotein lipase's ticket to ride. Cell Metab 12 (1) : 1-2, 2010.
PubMed
7) Davies B S : GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab 12 (1) : 42-52, 2010.
PubMed
8) Barish G D, et al : PPARs and LXRs : atherosclerosis goes nuclear. Trends Endocrinol Metab 15 (4) : 158-165, 2004.
PubMed
9) Schultz J R, et al : Role of LXRs in control of lipogenesis. Genes Dev 14 : 2831-2838, 2000.
PubMed
P.27 掲載の参考文献
1) Moreton J R : Atherosclerosis and Alimentary Hyperlipemia. Science 106 (2748) : 190-191, 1947.
PubMed
2) Rosenman R H, et al : Coronary heart disease in Western Collaborative Group Study. Final follow-up experience of 8 1/2 years. JAMA 233 (8) : 872-877, 1975.
 
3) Aberg H, et al : Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris. Results from a 10-year follow-up of Uppsala primary preventive study. Atherosclerosis 54 (1) : 89-97, 1985.
 
4) Lapidus L, et al : Triglycerides-main lipid risk factor for cardiovascular disease in women? Acta Med Scand 217 (5) : 481-489, 1985.
PubMed
5) Bainton D, et al : Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J 68 (1) : 60-66, 1992.
PubMed
6) Iso H, et al : Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women : the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis 237 (1) : 361-368, 2014.
PubMed
7) Wilhelmsen L, et al : Multivariate analysis of risk factors for coronary heart disease. Circulation 48 (5) : 950-958, 1973.
PubMed
8) Salonen J T, et al : Relation of serum cholesterol and triglycerides to the risk of acute myocardial infarction, cerebral stroke and death in eastern Finnish male population. Int J Epidemiol 12 (1) : 26-31, 1983.
 
9) Pocock S J, et al : Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. BMJ 298 (6679) : 998-1002, 1989.
PubMed
10) Crigui M H, et al : Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 328 (17) : 1220-1225, 1993.
 
11) Patsch J R, et al : Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 12 (1) : 1336-1345, 1992.
 
12) Zilversmit D B : Atherogenesis : a postprandial phenomenon. Circulation 60 (3) : 473-485, 1979,
PubMed
13) Mora S, et al : Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 118 (10) : 993-1001, 2008.
PubMed
14) Patel A, et al : Serum Triglycerides as a Risk Factor for Cardiovascular Diseases in the Asia-Pacific Region. Circulation 110 (17) : 2678-2686, 2004.
 
15) Sarwar N, et al : Triglycerides and the Risk of Coronary Heart Disease 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies. Circulation 115 (4) : 450-458, 2007.
PubMed
16) Do R, et al : Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 45 (11) : 1345-1352, 2013.
PubMed
17) Holmes M V, et al : Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 36 (9) : 539-550, 2015.
PubMed
18) White J, et al : Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. JAMA Cardiol 1 (6) : 692-699, 2016.
PubMed
19) Shahar E, et al : Plasma Lipid Profile and Incident Ischemic Stroke : the Atherosclerosis Risk in Communities (ARIC) study. Stroke 34 (3) : 623-631, 2003.
PubMed
20) Lindenstrem E, et al : Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease : the Copenhagen City Heart Study. BMJ 309 (6946) : 11-15, 1994.
 
21) Freiberg J J, et al : Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 300 (18) : 2142-2152, 2008.
PubMed
22) Hindy G, et al : Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes : A Mendelian Randomization Study. Stroke 49 (4) : 820-827, 2018.
PubMed

第2章 病因・病態生理

P.36 掲載の参考文献
1) Fredrickson D S, et al : Familial hyperlipoproteinemia. In : The Metabolic Basis of Inherited Disease, 3rd ed (Stanbury J B, et al. eds), p545-614. MacGraw-Hill, New York, 1972.
 
2) 後藤田貴也 : 家族性リポタンパクリパーゼ欠損症. 別冊日本臨床 先天代謝異常症候群 (第2版下巻) p15-19. 日本臨床社, 2012.
 
3) 後藤田貴也 : 家族性アポタンパクC II欠損症. 先天代謝異常ハンドブック (遠藤文夫編), p364-365. 中山書店, 2013.
 
4) Beigneux A P, et al : Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 5 (4) : 279-291, 2007.
 
5) Wang J, et al : Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol 27 (11) : 2450-2455, 2007.
PubMed
6) Peterfy M, et al : Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Nat Genet 39 (12) : 1483-1487, 2007.
PubMed
7) Lewis G F, et al : Hypertriglyceridemia in the genomic era : a new paradigm. Endocr Rev 36 (1) : 131-147, 2015.
 
8) Gotoda T, et al : Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb 19 (1) : 1-12, 2012.
 
9) Johansen C T, et al : Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 42 (8) : 684-687, 2010.
PubMed
10) Hegele R A, et al : The polygenic nature of hypertriglyceridemia : implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2 (8) : 655-666, 2014.
PubMed
11) Global Lipids Genetics Consortium : Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466 (7307) : 707-713, 2010.
 
12) Willer C J, et al : Discovery and refinement of loci associated with lipid levels. Nat Genet 45 (11) : 1274-1283, 2013.
PubMed
13) Johansen C T, et al : Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol 22 (4) : 247-253, 2011.
PubMed
14) Brunzell J D, et al : Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 24 (2) : 147-155, 1983.
PubMed
15) Johansen C T, et al : Allelic and phenotypic spectrum of plasma triglycerides. Biochim Biophys Acta 1821 (5) : 833-842, 2012.
PubMed
P.42 掲載の参考文献
1) Iso H et al : Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 153 : 490-499, 2001.
PubMed
2) Lynn E : Eberly, Jeremiah Stamler, James D. Neaton, Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease. Arch Intern Med 163 (9) : 1077-1083, 2003.
PubMed
3) Cooper A D : Hepatic uptake of chylomicron remnants. J Lipid Res 38 : 2173-2192, 1997.
PubMed
4) Fujioka Y, et al : Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 16 : 145-154, 2009.
PubMed
5) Fujioka Y, et al : Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages. J Lipid Res 39 : 2339-2349, 1998.
PubMed
6) Brown M, et al : A macrophage receptor for apolipoprotein B 48 : cloning, expression, and atherosclerosis. Proc Natl Acad Sci U S A 97 : 7488-7493, 2000.
 
7) Bermudez B, et al : Triglyceride-Rich Lipoprotein Regulates APOB48 Receptor Gene Expression in Human THP-1 Monocytes and Macrophages. J Nutr 142 : 227-232, 2012.
PubMed
8) Karpe F : Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 246 : 341-355, 1999.
PubMed
9) Masuda D, et al : Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia. J Atheroscler Thromb 18 : 1062-1070, 2011.
PubMed
10) McNamara J R : Remnant like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women : results from the Framingham Heart Study. Atherosclerosis 154 : 229-236, 2001.
PubMed
11) Nakatani K, et al : Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels. Atherosclerosis 218 : 226-232, 2011.
PubMed
12) Mohrschladt M, et al : Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy. Atherosclerosis 148 : 413-419, 2000.
PubMed
13) Eriksson P, et al : Very-Low-Density Lipoprotein Response Element in the Promoter Region of the Human Plasminogen Activator Inhibitor-1 Gene Implicated in the Impaired Fibrinolysis of Hypertriglyceridemia. Arterioscler Thromb Vasc Biol 18 : 20-26, 1998.
PubMed
14) Kawakami A, et al : Remnant Lipoprotein-Induced Smooth Muscle Cell Proliferation Involves Epidermal Growth Factor Receptor Transactivation. Circulation 108 : 2679-2688, 2003.
PubMed
15) Kawakami A, et al : Atorvastatin attenuates remnant lipoproteininduced monocyte adhesion to vascular endothelium under flow conditions. Circ Res 91 : 263-271, 2002.
PubMed
16) Doi H, et al : Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 102 : 670-676, 2000.
PubMed
17) Park S Y, et al : Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther 312 : 1241-1248, 2005.
PubMed
18) Pitas R E, et al : Foam cells in explants of atherosclerotic rabbit aortas have receptors for beta-very low density lipoproteins and modified low density lipoproteins. Arteriosclerosis 3 : 2-12, 1983.
PubMed
19) Pal S, et al : Identification of lipoproteins of intestinal origin in human atherosclerotic plaque. Clin Chem Lab Med 41 : 792-795, 2003.
PubMed
20) Jorgensen A B, et al : Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 34 (24) : 1826-1833, 2013.
PubMed
21) Forte T M, et al : Apolipoprotein A5 : Extracellular and Intracellular Roles in Triglyceride MetaboUsm. Curr Drug Targets 16 (12) : 1274-1280, 2015.
PubMed
22) Yoshida H, et al : Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C). Lipids Health Dis 7 : 18, 2008.
 
23) Kugiyama K, et al : Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99 : 2858-2860, 1999.
PubMed
24) Funada J I, et al : The close relationship between postprandial remnant metabolism and insulin resistance. Atherosclerosis 172 : 151-154, 2004.
 
25) Kinoshita M, et al : Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta 351 (1-2) : 115-120, 2005.
PubMed
26) Sakai N, et al : Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 44 : 1256-1262, 2003.
PubMed
27) Masuda D, et al : Reference Interval for the Apolipoprotein B-48 Corlcentration in Healthy Japanese Individuals. J Atheroscler Thromb 21 : 618-627, 2014.
PubMed
28) Yuasa-Kawase M, et al : Apolipoprotein B-48 to triglyceride ratio is a novel and useful marker for detection of type III hyperlipidemia after anti-hyperlipidemic intervention. J Atheroscler Thromb 19 : 862-871, 2012.
 
29) Okubo M, et al : Serum apolipoprotein B-48 concentration is associated with a reduced estimated glomerular filtration rate and increased proteinuria. J Atheroscler Thromb 21 : 974-982, 2014.
PubMed
P.50 掲載の参考文献
1) 田中明, 他 : 動脈硬化疾患におけるRLP-コレステロール (レムナント様リポ蛋白-コレステロール) 測定の臨床的意義. Prog Med 13 : 1215-1222, 1993.
 
2) Fukushima H, et al : Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J Am Coll Cardiol 43 (12) : 2219-2224, 2004.
PubMed
3) Nakamura T, et al : Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 181 (2) : 321-327, 2005.
PubMed
4) Kugiyama, et al : Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99 (22) : 2858-2860, 1999.
PubMed
5) Nguyen S V, et al : High remnant lipoprotein predicts recurrent cardiovascular events on statin treatment after acute coronary syndrome. Circ J 78 (10) : 2492-2500, 2014.
PubMed
6) Nguyen S V, et al : Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease. J Cardiol 69 (3) : 529-535, 2017.
PubMed
7) Nakamura T, et al : Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis 218 (1) : 163-167, 2011.
PubMed
8) Sano K, et al : Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein. Circ J 74 (8) : 1644-1650, 2010.
PubMed
9) Nakamura T, et al : A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J Cardiol 60 (1) : 12-17, 2012.
 
P.59 掲載の参考文献
1) Reaven G M, et al : Diabetic hypertriglyceridemia : evidence for three clinical syndromes. Diabetes 30 (Suppl 2) : 66-75, 1981.
 
2) Taskinen M R : Diabetic dyslipidaemia : from basic research to clinical practice. Diabetologia 46 : 733-749, 2003.
PubMed
3) Sone H, et al : Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes : subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 96 : 3448-3456, 2011.
 
4) Duez H, et al : Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 117 : 2369-2376, 2008.
PubMed
5) Brunzell J D, et al : Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 52 : 1578-1585, 1973.
 
6) Davis R A, et al : A polipoprotein B is both integrated into and translocated across the endoplasmic reticulum membrane. Evidence for two functionally distinct pools. J Biol Chem 265 : 10005-10011, 1990.
 
7) Dixon J L, et al : Hepatic synthesis of lipoproteins and apolipoproteins. Semin Liver Dis 12 : 364-372, 1992.
PubMed
8) Choi S H, et al : Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab 22 : 353-363, 2011.
PubMed
9) Furukawa S, et al : Rapid stimulation of apolipoprotein B secretion by oleate is not associated with cholesteryl ester biosynthesis in HepG2 cells. Biochim Biophys Acta 1170 : 32-37, 1993.
 
10) Horton J D, et al : SREBPs : activators of the complete program of cholesterol and fatty acidsynthesis in the liver. J Clin Invest 109 : 1125-1131, 2002.
 
11) Kubota N, et al : Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity. Nat Commun 7 : 12977, 2016.
PubMed
12) Phung T L, et al : Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J Biol Chem 272 : 30693-30702, 1997.
 
13) Lewis G F, et al : Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95 : 158-166, 1995.
PubMed
14) Biddinger S B, et al : Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 7 : 95-96, 2008.
 
15) Suga A, et al : Plasma leptin levels and triglyceride secretion rates in VMH-lesioned obese rats : a role of adiposity. Am J Physiol 276 : E650-657, 1999.
PubMed
16) Verges B : Pathophysiology of diabetic dyslipidaemia : where are we? Diabetologia 58 : 886-899, 2015.
PubMed
17) Hirano T T, et al : A poprotein C-III deficiency markedly stimulates triglyceride secretion in vivo : comparison with apoprotein E. Am J Physiol Endocrinol Metab 281 : E665-669, 2001.
 
18) Kaumi T, et al : VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM : effects of dietary fructose alone or in combination with pioglitazone. Diabetes 45 : 806-811, 1996.
PubMed
19) Kageyama H, et al : Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma. Biochem Biophys Res Commun 305 : 22-27, 2003.
 
20) Nagashima K, et al : Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 115 : 1323-1332, 2005.
PubMed
P.66 掲載の参考文献
1) Khera A V, et al : Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364 (2) : 127-135, 2011.
PubMed
2) Rosenson R S, et al : HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 57 (3) : 392-410, 2011.
PubMed
3) Tani M, et al : High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency. Atherosclerosis 253 : 7-14, 2016.
PubMed
4) Frenais R, et al : High density lipoprotein apolipoprotein AI kinetics in NIDDM : a stable isotope study. Diabetologia 40 (5) : 578-583, 1997.
PubMed
5) Barrans A, et al : Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem 269 (15) : 11572-11577, 1994.
PubMed
6) Rashid S, et al : Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol 22 (3) : 483-487, 2002.
PubMed
7) Srivastava R A K : Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. Mol Cell Biochem 440 (1-2) : 167-187, 2018.
 
P.74 掲載の参考文献
1) Brown M S, et al : The SREBP Pathway : Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor Cell 89 : 331-340, 1997.
PubMed
2) Shimano H, et al : SREBP-regulated lipid metabolism : convergent physiology-divergent pathophysiology. Nat Rev Endocrinol 13 (12) : 710-730, 2017.
PubMed
3) Shimano H : Sterol regulatory element-binding proteins (SREBPs) : Transcriptional regulators of lipid synthetic genes. Progress in Lipid Research 40 : 439-452, 2001.
PubMed
4) Oishi Y, et al : SREBP1 Contributes to Resolution of Pro-inflammatory TLR4 Signaling by Reprogramming Fatty Acid Metabolism. Cell Metab 25 (2) : 412-427, 2017.
PubMed
5) 島野仁 : 脂肪酸合成の量的制御と臓器脂肪酸組成の質的制御 : SREBP-1cとElovl6. 医のあゆみ 248 (13) : 1184-1189, 2014.
Medical*Online
6) Shimano H : SREBPs : physiology and pathophysiology of the SREBP family. FEBS J 276 (3) : 616-621, 2009.
PubMed
7) Yoshikawa T, et al : Identification of LXR/RXR as an Activator of the Sterol Regulatory Element-Binding Protein (SREBP) -1c Gene Promoter. Mol Cell Biol 21 (9) : 2991-3000, 2001.
PubMed
8) Linden A G, et al : Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice. J Lipid Res 59 (3) : 475-487, 2018.
PubMed
9) Takeuchi Y, et al : Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding Protein-l through proteolytic processing and autoloop regulatory circuit. J Biol Chem 285 (15) : 11681-11691, 2010.
 
10) Rong X, et al : ER phospholipid composition modulates lipogenesis during feeding and in obesity. J Clin Invest 127 (10) : 3640-3651, 2017.
 
11) Kammoun H L, et al : GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 119 (5) : 1201-1215, 2009.
PubMed
12) Ning J, et al : Constitutive role for IRE1α-XBP1 signaling pathway in the insulin-mediated hepatic lipogenic program Endocrinology 152 (6) : 2247-2255, 2011.
 
13) Peterson T R, et al : mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146 (3) : 408-420, 2011.
PubMed
14) Amemiya-Kudo M, et al : Promoter analysis of the mouse sterol regulatory element-binding protein-1c gene. J Biol Chem 275 (40) : 31078-31085, 2000.
 
15) Takeuchi Y, et al : KLF15 Enables Rapid Switching between Lipogenesis and Gluconeogenesis during Fasting. Cell Rep 16 (9) : 2373-2386, 2016.
PubMed
16) Rong S, et al : Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice. Elife 6 : pii : e25015, 2017.
 
17) Ide T, et al : SREBPz suppress IRS-2-mediated insulin signaling in the liver. Nat Cell Biol 6 : 351-357, 2004.
PubMed
18) Okazaki H, et al : LXR-SREBP-1c-phospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size. J Biol Chem 285 (9) : 6801-6810, 2010.
PubMed
19) Karasawa T : Sterol regulatory element-binding protein-1 determines plasma remnant lipoproteins and accelerates atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 31 (8) : 1788-1795, 2011.
PubMed
20) Takahashi A, et al : Transgenic mice overexpressing nuclear SREBP-1c in pancreatic beta-cells. Diabetes 54 : 492-499, 2005.
PubMed
21) Kato T, et al : Granuphilin is activated by SREBP-1c and involved in impaired insulin secretion in diabetic mice. Cell Metab 4 (2) : 143-154, 2006.
PubMed
22) Inoue N, et al : Lipid synthetic transcription factor SREBP-1a activates p21WAF1/CIP1, a universal cyclin-dependent kinase inhibitor. Mol Cell Biol 25 (20) : 8938-8947, 2005.
PubMed
23) Zhai X, et al : The β-catenin pathway contributes to the effects of leptin on SREBP-1c expression in rat hepatic stellate cells and liver fibrosis. Br J Pharmacol 169 (1) : 197-212, 2013.
 
P.84 掲載の参考文献
1) Kersten S : Physiological regulation of lipoprotein lipase. Biochim Biophys Acta 1841 : 919-933, 2014.
PubMed
2) Zechner R, et al : Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. J Lipid Res 50 : 3-21, 2009.
PubMed
3) Uno K, et al : A hepatic amino acid/mTOR/S6K-dependent signalling pathway modulates systemic lipid metabolism via neuronal signals. Nat Commun 6 : 7940, 2015.
PubMed
4) Uno K, et al : Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 312 : 1656-1659, 2006.
PubMed
5) Yamada T : Inter-organ communications mediate crosstalk between glucose and energy metabolism. Diabetol Int 4 (3) : 149-155 2013.
 
6) Izumida Y, et al : Glycogen shortage during fasting triggers liver-brain-adipose neurocircuitry to facilitate fat utilization. Nat Commun 4 : 2316, 2013.
PubMed
7) Cahill G F Jr : Starvation in Man. N Engl J Med 282 : 668-675, 1970.
 
8) Sawada Y, et al : Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry. Biochem Biophys Res Commun 493 : 40-45, 2017.
PubMed
9) Fisher F M, et al : Understanding the physiology of FGF21. Annu Rev Physiol 78 : 223-241, 2016.
PubMed
10) Kharitonenkov A, et al : FGF-21 as a novel metabolic regulator. J Clin Invest 5 : 1627-1635, 2005.
PubMed
11) Reitman M L : FGF 21 : a missing link in the biology of fasting. Cell Metab 5 : 405-407, 2007.
PubMed
12) Gaich G, et al : The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18 : 333-340, 2013.
PubMed
13) Talukdar S, et al : A Long-Acting FGF21 Molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab 23 : 427-440, 2016.
 
14) Kersten S : Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol 13 : 731-739, 2017.
PubMed
15) Koishi R, et al : Angptl3 regulates lipid metabolism in mice. Nat Genet 30 : 151-157, 2002.
PubMed
16) Musunuru K, et al : Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Eng J Med 363 : 2220-2227, 2010.
 
17) Wang Y, et al : Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proc Natl Acad Sci U S A 112 : 11630-11635, 2015.
PubMed
18) Dewey F E, et al : Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med 377 : 211-221, 2017.
PubMed
P.91 掲載の参考文献
1) Hotamisligil G S : Inflammation and metabolic disorders. Nature 444 : 860-867, 2006.
PubMed
2) Sun K, et al : Adipose tissue remodeling and obesity. J Clin Invest 121 : 2094-2101, 2011.
 
3) Suganami T, et al : Adipose tissue inflammation and ectopic lipid accumulation. Endocr J 59 : 849-857, 2012.
PubMed
4) Alisi A, et al : The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications. Mediators Inflamm 2017 : 2017.
PubMed
5) Lee B C, et al : Adipose Natural Killer Cells Regulate Adipose Tissue Macrophages to Promote Insulin Resistance in Obesity. Cell Metab 23 : 685-698, 2016.
PubMed
6) Suganami T, et al : A paracrine loop between adipocytes and macrophages aggravates inflammatory changes : Role of free fatty acids and tumor necrosis factor-α. Arterioscler Thromb Vasc Biol 25 : 2062-2068, 2005.
 
7) Suganami T, et al : Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun 354 : 45-49, 2007.
PubMed
8) Tanaka M, et al : Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis. Nat Commun 5 : 4982, 2014.
PubMed
9) Choe S S, et al : Adipose tissue remodeling : Its role in energy metabolism and metabolic disorders. Front Endocrinol 7 : 1-16, 2016.
 
10) Younossi Z, et al : Global burden of NAFLD and NASH : Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15 : 11-20, 2018.
PubMed
11) Itoh M, et al : Hepatic crown-like structure : A unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLoS One 8 : e82163, 2013.
PubMed
12) Fujii M, et al : CTLA-4Ig immunotherapy of obesity-induced insulin resistance by manipulation of macrophage polarization in adipose tissues. Biochem Biophys Res Commun 438 : 103-109, 2013.
PubMed
13) Komiya C, et al : Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci Rep 7 : 1-12, 2017.
 
14) Dixon J B, et al : Weight loss and non-alcoholic fatty liver disease : Falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 16 : 1278-1286, 2006.
PubMed
15) Gleeson M, et al : The anti-inflammatory effects of exercise : Mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 11 : 607-610, 2011.
PubMed
16) Lyons C L, et al : Metabolic inflammation-differential modulation by dietary constituents. Nutrients 8 : pii : E247, 2016.
 
17) Oh D Y, et al : GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects. Cell 142 : 687-698, 2010.
PubMed
P.93 掲載の参考文献
1) Beigneux A P, et al : N Engl J Med 376 : 1647, 2017.
PubMed

第3章 診断

P.100 掲載の参考文献
1) 日本臨床化学会試薬専門委員会 : 血清中の中性脂肪濃度測定の勧告法. 臨化 25 (1) : 39-51, 1996.
 
2) 渡部俊之 : トリグリセライド (TG) の代謝と測定法の問題点. 臨化 46 (2) : 127-132, 2017.
 
3) Nakagawa T, et al : Triglyceride concentrations should be measured after elimination of free glycerol to exclude interindividual variations due to adiposity and fasting status. Clin Chem Lab Med 55 (9) : e191-e194, d2017.
 
4) 日本動脈硬化学会編 : 動脈硬化性疾患予防ガイドライン 2017年版. p14. 日本動脈硬化学会, 東京, 2017.
 
5) Nordestgaard B G, et al : Fasting is not routinely required for determination of a lipid profile : clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 37 (25) : 1944-1958, 2016.
 
6) Pownall H J : Dietary ethanol is associated with reduced lipolysis of intestinally derived lipoproteins. J Lipid Res 35 (12) : 2105-2113, 1994.
PubMed
7) Miida, et al : LDL-cholesterol and HDL-cholesterol concentrations decrease during the day. Ann Clin Biochem 39 (Pt 3) : 241-249, 2002.
 
8) Kosuge K, et al : Estimating the fasting triglyceride concentration from the postprandial HDL-cholesterol and apolipoprotein C III concentrations. Atherosclerosis 184 (2) : 413-419, 2006.
PubMed
9) Miida T, et al : Plasma lipoprotein profiles change significantly during cardiac catheterization. Clin Chem 44 (3) : 517-521, 1998.
PubMed
10) 松原朱實 : 総コレステロール値が1日で40mg/dlも下がってます! Med Technol 41 (4) : 457-464, 2013.
Medical*Online
11) Idei M, et al : Mean postprandial triglyceride concentration is an independent risk factor for carotid atherosclerosis in patients with type 2 diabetes. Clin Chim Acta 430 : 134-139, 2014.
PubMed
P.106 掲載の参考文献
1) 日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン2017年. 2017.
Medical*Online
2) 日本動脈硬化学会 : 脂質異常症診療ガイド 2018年. 2018.
Medical*Online
P.107 掲載の参考文献
1) Hirano K, et al : N Engl J Med 359 : 2396, 2008.
PubMed
2) Hirano K, et al : Eur Heart J 36 : 580, 2015.
PubMed
3) Ikeda Y, et al : Eur Heart J 35 : 875, 2014.
PubMed
4) Hirano K, et al : Biochem Biophys Res Commun 443 : 574, 2014.
PubMed
5) 平野賢一 : 日内会誌 106 : 2385, 2017.
 

第4章 管理・治療

P.117 掲載の参考文献
1) 日本動脈硬化学会 : 動脈硬化性疾患予防のための脂質異常症診療ガイド 2018年版
Medical*Online
2) Mateo-Gallego R, et al : Serum lipid responses to weight loss differ between overweight adults with familial hypercholesterolemia and those with familial combined hyperlipidemia. J Nutr 144 : 1219-1226, 2014.
PubMed
3) Dubois C, et al : Effects of graded amounts (0-50g) of dietary fat on postprandial lipemia and lipoproteins in normolipidemic adults. Am J Clin Nutr 67 : 31-38, 1998.
 
4) Schwingshackl L, et al : Comparison of effects of long-term low-fat vs high-fat diets on blood lipid levels in overweight or obese patients : a systematic review and meta-analysis. J Acad Nutr Diet 113 : 1640-1661, 2013.
PubMed
5) Yokoyama A, et al : Alcohol dehydrogenase-1B (rs1229984) and aldehyde dehydrogerlase-2 (rs671) genotypes are strong determinants of the serum triglyceride and cholesterol levels of Japanese alcoholic men. PLoS ONE 10 : e0133460, 2015.
PubMed
6) Leslie M A, et al : A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals. Lipids Health Dis 14 : 53, 2015.
PubMed
P.122 掲載の参考文献
1) Durstine J L, et al : Blood lipid and lipoprotein adaptations to exercise : a qantitative analysis. Sports Med 31 : 1033-1062, 2001.
 
2) Durstine J L, et al : Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil 22 : 385-398, 2002.
PubMed
3) Wang Y, et al : Effects of aerobic exercise on lipids and lipoproteins0 Lipids Health Dis 16 : 132, 2017.
 
4) Couillard C, et al : Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides : evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 21 : 1226-1232, 2001.
PubMed
5) Bansal S, et al : Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298 (3) : 309-316, 2007.
PubMed
6) Burton F L, et al : Energy replacement attenuates the effects of prior moderate exercise on postprandial metabolism in overweight/obese men. Int J Obes 32 : 481-489, 2008.
 
7) Seip R L, et al : Exercise induces human lipoprotein lipase gene expression in skeletal muscle but not adipose tissue. Am J Physiol 268 : E229-E236, 1995.
PubMed
8) Hamilton M T, et al : Role of local contractile activity and muscle fiber type on LPL regulation during exercise. Am J Physiol 275 : E1016-E1022, 1998.
PubMed
9) Seip R L, et al : Skeletal muscle lipoprotein lipase : molecular regulation and physiological effects in relation to exercise. Exerc Sports Sci Rev 26 : 191-218, 1998.
PubMed
10) 勝川史憲 : 運動と食事摂取のタイミング : 食前の運動は有効か? 日抗加齢医会誌 5 : 864-866, 2009.
 
11) Herd S L, et al : Moderate exercise, postprandial lipemia and skeletal muscle lipoprotein lipase activity. Metabolism 50 : 756-762, 2001.
PubMed
12) Gill J M R, et al : Effects of a brisk walk on lipoprotein lipase activity and plasma triglyceride concentration in the fasted and postprandial states. Eur J Appl Physiol 89 : 184-190, 2003.
PubMed
13) Peddie M C, et al : Physical activity and postprandial lipidemia : are energy expenditure and lipoprotein lipase activity the real modulators of the positive effect? Prog Lipid Res 51 : 11-22, 2012.
PubMed
14) Katsanos C S, et al : Acute effects of premeal versus postmeal exercise on postprandial hypertriglyceridemia. Clin J Sport Med 14 : 33-39, 2004.
PubMed
15) Malkova D, et al : Prior exercise and postprandial substrate extraction across the human leg. Am J Physiol 279 : E1020-1028, 2000.
 
16) Petitt D S, et al : Effects of prior exercise on postprandial lipemia : a quantitative review. Metabolism 52 : 418-424, 2003.
PubMed
17) Mestek M L, et al : Aerobic exercise and postprandial lipemia in men with the metabolic syndrome. Med Sci Sports Exerc 40 : 2105-2011, 2008.
PubMed
18) Singhal A, et al : Effect of intensity of resistance exercise on postprandial lipemia. J Appl Physiol 106 : 823-829, 2009.
PubMed
19) Burns S F, et al : High-Intensity Interval Exercise and Postprandial Triacylglycerol. Sports Med 45 : 957-968, 2015.
PubMed
20) Xie C, et al : Effects of high-intensity interval training on aerobic capacity in cardiac patients : a systematic review with meta-analysis. Biomed Res Int 2017 : 5420840, 2017.
 
21) Crichton G E, et al : Physical activity, sedentary behavior time and lipid levels in the Observation of Cardiovascular Risk Factors in Luxembourg study. Lipids Health Dis 14 : 87, 2015.
PubMed
22) Wang X, et al : Objectively measured sedentary time and cardiovascular risk factor control in US Hispanics/Latinos with diabetes mellitus : results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). J Am Heart Assoc 6 : pii : e004324, 2017.
 
P.131 掲載の参考文献
1) 日本動脈硬化学会編 : 動脈硬化性疾患予防ガイドライン2017年版. 日本動脈硬化学会, 2017.
 
2) Hokanson J E, et al : Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level : a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (2) : 213-219, 1996.
 
3) Okamura T, et al : A revised definition of the metabolic syndrome predicts coronary artery disease and ischemic stroke after adjusting for low density lipoprotein cholesterol in a 13-year cohort study of Japanese : the Suita study. Atherosclerosis 217 (1) : 201-206, 2011.
 
4) Iso H, et al : Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 153 : 490-499, 2001.
PubMed
5) Fujioka Y, et al : Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages. J Lipid Res 39 : 2339-2349, 1998.
PubMed
6) Masuda D, et al : Postprandial Hyperlipidemia and Remnant Lipoproteins. J Atheroscler Thromb 24 (2) : 95-109, 2017.
PubMed
7) Sakai N, et al : Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 44 : 1256-1262, 2003.
PubMed
8) Masuda D, et al : Fasting Serum Apolipoprotein B-48 Can be a Marker of Postprandial Hyperlipidemia. J Atheroscler Thromb 18 (12) : 1062-1070, 2011.
PubMed
9) Masuda D, et al : Reference interval for the apolipoprotein B-48 concentration in healthy Japanese individuals. J Atheroscler Thromb 21 (6) : 618-627, 2014.
PubMed
10) Okubo M, et al : Serum Apolipoprotein B-48 Concentration Is Associated with a Reduced Estimated Glomerular Filtration Rate and Increased Proteinuria J Atheroscler Thromb 21 : 974-982, 2014.
PubMed
11) Masuda D, et al : Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur J Clin Invest 42 (9) : 992-999, 2012.
PubMed
12) Yuasa-Kawase M, et al : Apolipoprotein B-48 to Triglyceride Ratio Is a Novel and Useful Marker for Detection of Type III Hyperlipidemia after Antihyperlipidemic Intervention. J Atheroscler Thromb 19 (9) : 862-871, 2012.
 
13) Sandoval J C, et al : Fenofibrate Reduces Postprandial Hypertriglyceridemia in CD36 Knockout Mice. J Atheroscler Thromb 17 (6) : 610-618, 2010.
PubMed
14) Sahebkar A : Circulating levels of proprotein convertase subtilism kexin type9 are elevated by fibrate therapy : a systematic review and meta-analysis of clinical trials. Cardiol Rev 22 : 306-312, 2014.
 
15) Bezafibrate Infarction Prevention (BIP) study : Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102 (1) : 21-27, 2000.
PubMed
16) Goldenberg I, et al : Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia : an extended follow-up of the BIP trial. J Am Coll Cardiol 51 (4) : 459-465, 2008.
 
17) Keech A, et al : Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) : randomised controlled trial. Lancet 366 (9500) : 1849-1861, 2005.
 
18) ACCORD Study Group, et al : Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (17) : 1563-1574, 2010.
 
19) Wang D, et al : Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev CD009580, 2015.
PubMed
20) Ishibashi S, et al : Effects of K-877, a novel selective PPARαmodulator (SPPARMα), in dyslipidaemic patients : A randomized, double blind, active-and placebo-controlled, phase 2 trial. Atherosclerosis 249 : 36-43, 2016.
 
21) Liu Z M, et al : Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. Expert Opin Investig Drugs 24 (5) : 611-621, 2015.
 
22) Sairyo M, et al : A Novel Selective PPARαModulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice. J Atheroscler Thromb 25 (2) : 142-152, 2018.
 
P.141 掲載の参考文献
1) 日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン 2017年度版. 2017.
 
2) 山下静也 : 栄養素から考える心血管病「不飽和脂肪酸と心血管疾患」. 循環器内科 75 : 571-579, 2014.
 
3) Mori K, et al : Serum Trans-Fatty Acid Concentration Is Elevated in Young Patients With Coronary Artery Disease in Japan. Circ J 79 : 2017-2025, 2015.
PubMed
4) 内閣府食品安全委員会 : 「食品に含まれるトランス脂肪酸に係る食品健康影響評価情報に関する評価」. 2011.
 
5) Dyerberg J, et al : Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet 2 : 117-119, 1978.
PubMed
6) Ninomiya T, et al : Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease : the Hisayama Study. Atherosclerosis 231 : 261-267, 2013.
PubMed
7) Aung T, et al : Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks : Meta-analysis of 10 Trials Involving 77917 Individuals. JAMA Cardiology 3 : 225-234, 2018.
 
8) Iso H, et al : Serum fatty acids and fish intake in rural Japanese, urban Japanese, Japanese American and Caucasian American men. Int J Epidemiol 18 : 374-381, 1989.
PubMed
9) Iso H, et al : Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese : the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 113 : 195-202, 2006.
PubMed
10) Yamagishi K, et al : Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J Am Coll Cardiol 52 : 988-996, 2008.
 
11) Miyagawa N, et al : Long-chain n-3 polyunsaturated fatty acids intake and cardiovascular disease mortality risk in Japanese : a 24-year follow-up of NIPPON DATA80. Atherosclerosis 232 : 384-389, 2014.
PubMed
12) Marchioli R, et al : Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction : time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) -Prevenzione. Circulation 105 : 1897-1903, 2002.
 
13) Yokoyama M, et al : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet 369 : 1090-1098, 2007.
PubMed
14) Musa-Veloso K, et al : Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides. Nutr Rev 68 : 155-167, 2010.
PubMed
15) Mozaffarian D, et al : Omega-3 fatty acids and cardiovascular disease : effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58 : 2047-2067, 2011.
PubMed
16) Wei M Y, et al : Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids : a systematic review and meta-analysis. Curr Atheroscler Rep 13 : 474-483, 2011.
PubMed
17) Agren J J, et al : Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels. Eur J Clin Nutr 50 : 765-771, 1996.
PubMed
18) Saito Y, et al : Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors : sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200 : 135-140, 2008.
PubMed
19) Tanaka N, et al : Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia. Atherosclerosis 237 : 577-583, 2014.
PubMed
20) Masuda D, et al : Postprandial Hyperlipidemia and Remnant Lipoproteins. J Atheroscler Thromb 24 : 95-109, 2017.
PubMed
21) Jacobson T A, et al : Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids : a review. J Clin Lipidol 6 : 5-18, 2012.
PubMed
22) 平澤明, 他 : 消化管脂肪酸受容体とその生理作用. 薬誌 131 : 1683-1689, 2011.
Medical*Online
23) Schwab J M, et al : Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447 : 869-874, 2007.
PubMed
P.148 掲載の参考文献
1) Tatami R, et al : Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 64 : 1174-1184, 1981.
PubMed
2) Liu J, et al : Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 98 : 1363-1368, 2006.
PubMed
3) Hirowatari Y, et al : Measurement of cholesterol of major serum lipoprotein classes by anion-exchange HPLC with perchlorate ion-containing eluent. J Lipid Res 44 : 1404-1412, 2003.
PubMed
4) 吉田博 : リポ蛋白分析 : リポ蛋白分画の評価と陰イオン交換クロマトグラフィー法. 臨病理 64 : 643-650, 2016.
Medical*Online
5) Manita D, et al : A rapid anion-exchange chromatography for measurement of cholesterol concentrations in five lipoprotein classes and estimation of lipoprotein profiles in male volunteers without overt diseases. Ann Clin Biochem 52 (Pt 6) : 638-646, 2015.
 
6) Lamon-Fava S, et al : Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J Lipid Res 48 : 1746-1753, 2007.
 
7) Nissen S E, et al : Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis : a randomized controlled trial. JAMA 291 : 1071-1080, 2004.
 
8) Yoshida H, et al : Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis 226 : 161-164, 2013.
PubMed
9) LaRosa J C, et al : Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 : 1425-1435, 2005.
PubMed
10) Taguchi I, et al : High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD) : A Randomized Superiority Trial. Circulation 137 : 1997-2009, 2018.
PubMed
11) Yokoyama M, et al : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet 369 : 1090-1098, 2007.
PubMed
12) Nosaka K, et al : Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes : 1-year outcomes of a randomized controlled study. Int J Cardiol 228 : 173-179, 2017.
PubMed
13) ACCORD Study Group, et al : Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 : 1563-1574, 2010.
 
14) Keech A, et al : Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) : randomised controlled trial. Lancet 366 : 1849-1861, 2005.
 
15) 吉田博 : フィブラートとその治療のエビデンス. Current Therapy 32 : 903-907, 2014.
 
P.156 掲載の参考文献
1) Turley S D, et al : The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level. Prev Cardiol 6 (1) : 29-33, 64, 2003.
PubMed
2) Pandor A, et al : Ezetimibe monotherapy for cholesterol lowering in 2,722 people : systematic review and meta-analysis of randomized controlled trials. J Intern Med 265 : 568-580, 2009.
PubMed
3) Mikhailidis D P, et al : Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 23 (8) : 2009-2026, 2007.
PubMed
4) Stone N J, et al : 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology/American Heart Associatiorl Task Force on Practice Guidelines. J Am Coll Cardiol 63 (25) : 2889-2934, 2014.
 
5) Cannon C P, et al : Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372 (25) : 2387-2397, 2015.
PubMed
6) Stitziel N O, et al : Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Eng J Med 371 (22) : 2072-2082, 2014.
 
7) Wang H H, et al : Effect of Ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 134 (7) : 2101-2110, 2008.
PubMed
8) Teramoto T, et al : Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study. Cardiovasc Diabetol 12 : 163, 2013.
PubMed
9) Oikawa S, et al : Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia : Results of the EFECTL Study. J Atheroscler Thromb 24 (1) : 77-94, 2017.
PubMed
10) Shinnakasu A, et al : The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes. J Atheroscler Thromb 24 (7) : 735-748, 2017.
PubMed
11) Sone H, et al : Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes : subanalysis of the Japan Diabetes Complications Study UDCS). J Clin Endocrinol Metab 96 (11) : 3448-3456, 2011.
 
12) Masuda D, et al : Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 39 (8) : 689-698, 2009.
PubMed
13) Kikuchi K, et al : Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J Atheroscler Thromb 19 (12) : 1093-1101, 2012.
 
14) Assy N, et al : Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol 12 (27) : 4369-4376, 2006.
PubMed
15) Deushi M, et al : Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 581 (29) : 5664-5670, 2007.
PubMed
16) Gonzalez-Ortiz M, et al : Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc Drugs Ther 20 (2) : 143-146, 2006.
PubMed
P.165 掲載の参考文献
1) 原田英雄 : まれな膵炎とその成因-高脂血症-. 胆と膵 12 : 1063-1066, 1991.
 
2) Havel R J : Pathogenesis, differenciation and management of hypertriglyceridemia. Adv Intern Med 15 : 117-154, 1969.
 
3) Morita Y, et al : Involvement of lipid peroxidation in free fatty acid-induced isolated rat pancreatic acinar cell injury. Pancreas 17 : 383-389, 1998.
PubMed
4) Pandol S J, et al : Acute pancreatitis : bench to the bedside. Gastroenterology 132 (3) : 1127-1151, 2007.
 
5) Brunzell J D, et al : Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia. Med Clin North Am 66 (2) : 455-468, 1982.
PubMed
6) 大平征宏 : 脂質代謝関連検査法の進歩と臨床的意義リポ蛋白分析法. 日臨 65 (増刊号 7) : 147-152, 2007.
 
7) Talmud P J : Rare APOA5 mutations-clinical consequences, metabolic and functional effects : an ENID review. Atherosclerosis 194 (2) : 287-292, 2007.
PubMed
8) Kinoshita T, et al : The level of pre-heparin serum lipoprotein lipase mass at different stages of pregnancy. Clin Chim Acta 337 (1-2) : 153-156, 2003.
 
9) Zhu Y, et al : Severe hypertriglyceridemia with plasma inhibitory factor (s) on lipoprotein lipase activity in a patient with a common Ser (447) -Ter LPL mutation. Clin Chim Acta 308 (1-2) : 139-146, 2001,
 
10) Tamez-Perez H E, et al : Treatment of severe hypertriglyceridemia in nondiabetic patients with insulin. Am J Emerg Med 23 : 415-417, 2005.
 
11) Tsuang W, et al : Hypertriglyceridemic pancreatitis : presentation and management. Am J Gastroenterol 104 (4) : 984-991, 2009.
PubMed
12) Gotoda T, et al : Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb 19 (1) : 1-12, 2012.
 
13) Shirai K, et al : Type I hyperlipoproteinemia caused by lipoprotein lipase defect in lipid-interface recognition was relieved by administration of medium-chain triglyceride. Metabolism 41 (11) : 1161-1164, 1992.
PubMed
P.174 掲載の参考文献
1) 日本肝臓学会 : NASH・NAFLDの診療ガイド. 文光堂, 東京, 2015.
 
2) Tilg H, et al : Evolution of inflammation in nonalcoholic fatty liver disease : the multiple parallel hits hypothesis. Hepatology 52 (5) : 1836-1846, 2010.
 
3) Belfort R, et al : A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (22) : 2297-2307, 2006.
 
4) Cusi K, et al : Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus : a randomized trial. Ann Intern Med 165 (5) : 305-315, 2016.
 
5) Uygun A, et al : Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19 (5) : 537-544, 2004.
 
6) Lavine J E, et al : Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescerlts : the TONIC randomized controlled trial. JAMA 305 (16) : 1659-1668, 2011.
 
7) Chan D C, et al : Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet Diabetes Care 33 (5) : 1134-1139, 2010.
PubMed
8) Yoneda M, et al : Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis : An open-label, pilot study. Hepatol Res 40 (6) : 566-573, 2010.
PubMed
9) Foster T, et al : Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease : the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 106 (1) : 71-77, 2011.
 
10) Yokohama S, et al : Therapeutic efficacy of an angiotensin n receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40 (5) : 1222-1225, 2004.
 
11) Sanyal A J, et al : Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362 (18) : 1675-1685, 2010.
 
12) Sumida Y, et al : Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 53 (3) : 362-376, 2018.
 
13) Armstrong M J, et al : Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN) : a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (10019) : 679-690, 2016.
 
14) Zinman B, et al : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 (22) : 2117-2128, 2015.
PubMed
15) Shibuya T, et al : Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease : A prospective randomized controlled pilot study. Diabetes Obes Metab 20 (2) : 438-442, 2018.
PubMed
16) Honda Y, et al : Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep 7 : 42477, 2017.
 
17) Sugiura M, et al : High serum carotenoids are associated with lower risk for developing elevated serum alanine aminotransferase among Japanese subjects : the Mikkabi cohort study. Br J Nutr 115 (8) : 1462-1469, 2016.
PubMed
18) Ni Y, et al : Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice : A comparison with vitamin E. Sci Rep 5 : 17192, 2015.
PubMed
19) Ni Y, et al : Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin. Endocrinology 156 (3) : 987-999, 2015.
 
20) Kitade H, et al : Nonalcoholic Fatty Liver Disease and Insulin Resistance : New Insights and Potential New Treatments. Nutrients 9 (4) : 387, 2017.
PubMed
21) Kobori M, et al : β-Cryptoxanthin alleviates dietinduced nonalcoholic steatohepatitis by suppressing inflammatory gene expression in mice. PLoS One 9 (5) : e98294, 2014.
 
22) Zhang Y, et al : Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci U S A 91 (8) : 3147-3150, 1994.
PubMed
23) Juge N, et al : Molecular basis for chemoprevention by sulforaphane : a comprehensive review. Cell Mol Life Sci 64 (9) : 1105-1127, 2007.
PubMed
24) Malhorta D, et al : Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 38 (17) : 5718-5734, 2010.
 
25) Kobayashi E H, et al : Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun 7 : 11624, 2016.
PubMed
26) Nagata N, et al : Glucoraphanin Ameliorates Obesity and Insulin Resistance Through Adipose Tissue Browning and Reduction of Metabolic Endotoxemia in Mice. Diabetes 66 (5) : 1222-1236, 2017.
PubMed
P.183 掲載の参考文献
1) 日本腎臓学会 : エビデンスに基づくCKD診療ガイドライン 2013. 2013.
 
2) 庄司哲雄 : CKDと脂質異常症. 成人病と生活習慣病 43 : 81-87, 2013.
Medical*Online
3) Muntner P, et al : Traditional and Nontraditional Risk Factors Predict Coronary Heart Disease in Chronic Kidney Disease : Results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 16 : 529-538, 2005.
PubMed
4) Tsuruya K, et al : Impact of the Triglycerides to High-Density Lipoprotein Cholesterol Ratio on the Incidence and Progression of CKD : A Longitudinal Study in a Large Japanese Population. Am J Kidney Dis 66 : 972-983, 2015.
 
5) 日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン 2017年版. 2017.
Medical*Online
6) Baigent C, et al : The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebo-controlled trial. Lancet 377 (9784) : 2181-2192, 2011.
PubMed
7) Jun M, et al : Effects of Fibrates in Kidney Disease : A Systematic Review and Meta-Analysis. J Am Coll Cardiol 60 : 2061-2071, 2012.
PubMed
8) Terasawa R, et al : Bezafibrate suppresses the expression of TGF-β and type IV collagen in human mesangial cells loaded with remnant lipoproteins. Jpn Pharmacol Ther 37 (2) : 117-122, 2009.
 
P.191 掲載の参考文献
1) Rouis M, et al : Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome. Arterioscler Thromb Vasc Biol 17 : 1400-1406, 1997.
 
2) Stefanutti C, et al : Therapeutic plasma exchange in patients with severe hypertriglyceridemia : a multicenter study. Artif Organs 33 : 1096-1102, 2009.
PubMed
3) Stroes E S, et al : Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 28 : 2303-2304, 2008.
PubMed
4) Gaudet D, et al : Efficacy and lung-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency : an open-label trial. Gene Ther 20 : 361-369, 2013.
 
5) Hori S, et al : XRN2 is required for the degradation of target RNAs by RNase H1-dependent antisense oligonucleotides. Biochem Biophys Res Commun 464 : 506-511, 2015.
PubMed
6) Yamamoto T, et al : Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides. Bioorg Med Chem 24 : 26-32, 2016.
PubMed
7) Surendran R P, et al : Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med 272 : 185-196, 2012.
PubMed
8) Sundaram M, et al : Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res 51 : 150-161, 2010.
PubMed
9) Kersten S : Physiological regulation of lipoprotein lipase. Biochim Biophys Acta 1841 : 919-933, 2014.
PubMed
10) Jorgensen A B, et al : Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 371 : 32-41, 2014.
PubMed
11) Crosby J, et al : Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371 : 22-31, 2014.
PubMed
12) Yamamoto T, et al : Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma Eur J Pharmacol 723 : 353-359, 2014.
PubMed
13) Gaudet D, et al : Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med 373 : 438-447, 2015.
PubMed
P.198 掲載の参考文献
1) Sarwar N, et al : Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease : a collaborative meta-analysis of 102 prospective studies. Lancet 375 (9733) : 2215-2222, 2010.
PubMed
2) Turner R C, et al : Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus : United Kingdom Prospective Diabetes Study (UKPDS : 23). BMJ 316 (7134) : 823-828, 1998.
PubMed
3) メタボリックシンドローム診断規準検討委員会 : メタボリックシンドロームの定義と診断規準. 日内会誌 94 (4) : 794-809, 2005.
 
4) Nakamura T, et al : Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees : a case-control study. Jpn Circ J 65 (1) : 11-17, 2001.
PubMed
5) Toth P P, et al : The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 11 : 109, 2012.
PubMed
6) Kugiyama K, et al : Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344 (6262) : 160-162, 1990.
PubMed
7) Shoji T, et al : Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis 202 (2) : 582-588, 2009.
PubMed
8) Koba S, et al : Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis 189 (1) : 206-214, 2006.
 
9) 村本あき子 : 特定保健指導の効果検証. 肥満研 19 (2) : 75-81, 2013.
Medical*Online
10) Mensink R P, et al : Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins : a meta-analysis of 60 controlled trials. Am J Clin Nutr 77 (5) : 1146-1155, 2003.
PubMed
11) Schwingshackl L, et al : Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes : a systematic review and network meta-analysis. Diabetologia 57 (9) : 1789-1797, 2014.
PubMed
12) Keech A, et al : Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) : randomised controlled trial. Lancet 366 (9500) : 1849-1861, 2005.
 
13) Keech A C, et al : Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study) : a randomised controlled trial. Lancet 370 (9600) : 1687-1697, 2007.
PubMed
14) Allemann S, et al : Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus : meta-analysis of randomised controlled trials. Curr Med Res Opin 22 (3) : 617-623, 2006.
PubMed
15) Yokoyama M, et al : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised openlabel, blinded endpoint analysis. Lancet 369 (9567) : 1090-1098, 2007.
PubMed

書評

最近チェックした商品履歴

Loading...